{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:12:54Z","timestamp":1777536774354,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1992,8,1]],"date-time":"1992-08-01T00:00:00Z","timestamp":712627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1992,8]]},"DOI":"10.1007\/bf02245121","type":"journal-article","created":{"date-parts":[[2005,11,14]],"date-time":"2005-11-14T22:38:33Z","timestamp":1132007913000},"page":"338-344","source":"Crossref","is-referenced-by-count":44,"title":["Differences between antipsychotic drugs in persistence of brain levels and behavioral effects"],"prefix":"10.1007","volume":"108","author":[{"given":"Bruce M.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Tsuneizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross J.","family":"Baldessarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzann M.","family":"Babb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02245121_CR1","first-page":"346","volume":"52","author":"LD Alphs","year":"1991","unstructured":"Alphs LD, Lee HS (1991) Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 52:346\u2013348","journal-title":"J Clin Psychiatry"},{"key":"BF02245121_CR2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0006-8993(86)91547-7","volume":"385","author":"SM Antelman","year":"1986","unstructured":"Antelman SM, Kocan D, Edwards EJ, Knopf S, Perel JM, Stiller R (1986) Behavioral effects of a single neuroleptic treatment grow with the passage of time. Brain Res 385:58\u201367","journal-title":"Brain Res"},{"key":"BF02245121_CR3","first-page":"383","volume-title":"Goodman and Gilman's Pharmacologic basis of therapeutics","author":"RJ Baldessarini","year":"1990","unstructured":"Baldessarini RJ (1990) Drugs and treatment of psychiatric disorders. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) Goodman and Gilman's Pharmacologic basis of therapeutics, 8th edn. Pergamon Press, New York, pp 383\u2013435","edition":"8th edn."},{"issue":"2","key":"BF02245121_CR4","first-page":"1091","volume":"17","author":"RJ Baldessarini","year":"1991","unstructured":"Baldessarini RJ, Kula N, George T, Campbell, Bakthavachalam V, Neumeyer JL (1991) Recovery of central D1 and D2 receptors following alkylation in young and adult rat brain (Abs. 432.9). Neurosci Soc Abstr 17[2]:1091","journal-title":"Neurosci Soc Abstr"},{"key":"BF02245121_CR5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.120.6.578","volume":"120","author":"EM Caffey","year":"1963","unstructured":"Caffey EM, Forrest IS, Frank TV, Klett CJ (1963) Phenothiazine excretion in chronic schizophrenics. Am J Psychiatry 120:578","journal-title":"Am J Psychiatry"},{"key":"BF02245121_CR6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1192\/bjp.151.6.824","volume":"151","author":"H Cambon","year":"1987","unstructured":"Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Maziere B (1987) In vivo asay for neuroleptic receptor binding in the striatum \u2014 positron tomography in humans. Br J Psychiatry 151:824\u2013830","journal-title":"Br J Psychiatry"},{"key":"BF02245121_CR7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0024-3205(80)90002-8","volume":"27","author":"A Campbell","year":"1980","unstructured":"Campbell A, Herschel M, Cohen BM, Baldessarini RJ (1980) Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat. Life Sci 27:633\u2013640","journal-title":"Life Sci"},{"key":"BF02245121_CR8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0028-3908(82)90106-X","volume":"21","author":"A Campbell","year":"1982","unstructured":"Campbell A, Baldessarini RJ, Ram VJ, Neumeyer JL (1982) Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnorapomorphine, an orally effective long-acting agent active at central dopamine receptors, and analagous aporphines. Neuropharmacology 21:953\u2013961","journal-title":"Neuropharmacology"},{"key":"BF02245121_CR9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00431801","volume":"87","author":"A Campbell","year":"1985","unstructured":"Campbell A, Baldessarini RJ, Kula NS (1985) Prolonged antidopamine actions of single doses of butyrophenones in the rat. Psychopharmacology 87:161\u2013166","journal-title":"Psychopharmacology"},{"key":"BF02245121_CR10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF00735879","volume":"94","author":"A Campbell","year":"1988","unstructured":"Campbell A, Baldessarini RJ, Teicher MH (1988) Decreasing sensitivity to neuroleptic agents in developing rats; evidence for a pharmacodynamic factor. Psychopharmacology 94:46\u201351","journal-title":"Psychopharmacology"},{"key":"BF02245121_CR11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1176\/ajp.135.2.164","volume":"135","author":"A Carlsson","year":"1978","unstructured":"Carlsson A (1978) Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 135:164\u2013173","journal-title":"Am J Psychiatry"},{"key":"BF02245121_CR12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF00432230","volume":"86","author":"BM Cohen","year":"1985","unstructured":"Cohen BM, Zubenko GS (1985) In vivo effects of psychotropic agents on the physical properties of cell membranes in the rat brain. Psychopharmacology 86:365\u2013368","journal-title":"Psychopharmacology"},{"key":"BF02245121_CR13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archpsyc.1988.01800330113019","volume":"45","author":"BM Cohen","year":"1988","unstructured":"Cohen BM, Babb S, Campbell A, Baldessarini RJ (1988) Persistence of haloperidol in brain. Arch Gen Psychiatry 45:879\u2013880","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245121_CR14","first-page":"277","volume-title":"Advances in neuropsychiatry and psychopharmacology","author":"BM Cohen","year":"1991","unstructured":"Cohen BM, Baldessarini RJ, Campbell A, Tsuneizumi T, Babb SM (1991) Persistence of antipsychotic drug levels and effects. In: Tamminga CA, Schulz SC (eds) Advances in neuropsychiatry and psychopharmacology. Raven Press, New York, pp 277\u2013284"},{"key":"BF02245121_CR15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","volume":"192","author":"I Creese","year":"1976","unstructured":"Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481\u2013483","journal-title":"Science"},{"key":"BF02245121_CR16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archpsyc.1970.01740260093014","volume":"22","author":"SH Curry","year":"1970","unstructured":"Curry SH, Marshall JHL, Davis JM, Janowsky DS (1970) Chlorpromazine plasma levels and effects. Arch Gen Psychiatry 22:189\u2013196","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245121_CR17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cpt1977214437","volume":"21","author":"SG Dahl","year":"1977","unstructured":"Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21:437\u2013448","journal-title":"Clin Pharmacol Ther"},{"key":"BF02245121_CR18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/archpsyc.1991.01810250075011","volume":"48","author":"M Davidson","year":"1991","unstructured":"Davidson M, Kahn RS, Powchik P, Warne P, Losonczy MF, Kaminsky R, Apter S, Jaff S, Davis KL (1991) Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry 48:73\u201376","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl [9]","key":"BF02245121_CR19","first-page":"6","volume":"47","author":"L Ereshefsky","year":"1986","unstructured":"Ereshefsky L, Jann MW, Saklad SR, Davis CM (1986) Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J Clin Psychiatry 47 suppl [9]:6\u201315","journal-title":"J Clin Psychiatry"},{"key":"BF02245121_CR20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","volume":"45","author":"L Farde","year":"1988","unstructured":"Farde L, Wiesel F-A, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71\u201376","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245121_CR21","first-page":"396","volume":"21","author":"A Forsman","year":"1977","unstructured":"Forsman A, Ohman R (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21:396\u2013411","journal-title":"Curr Ther Res"},{"key":"BF02245121_CR22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/archpsyc.1987.01800130111024","volume":"44","author":"JW Hubbard","year":"1987","unstructured":"Hubbard JW, Ganes D, Midha KK (1987) Prolonged pharmacologic activity of neuroleptic drugs. Arch Gen Psychiatry 44:99\u2013100","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245121_CR23","first-page":"565","volume":"31","author":"H Itoh","year":"1977","unstructured":"Itoh H, Ohtsuka N, Ogita K, et al. (1977) Malignant neuroleptic syndrome: Its present state in Japan in clinical problems. Folia Psychiatr Neurol Japonica 31:565\u2013576","journal-title":"Folia Psychiatr Neurol Japonica"},{"key":"BF02245121_CR24","first-page":"361","volume":"26","author":"JI Javaid","year":"1990","unstructured":"Javaid JI, Sharma RP, Janicak PG, Davis JM (1990) Plasma HVA in psychiatric patients: longitudinal studies. Psychopharmacol Bull 26:361\u2013365","journal-title":"Psychopharmacol Bull"},{"issue":"[suppl]1","key":"BF02245121_CR25","first-page":"524","volume":"3","author":"PC Johnson","year":"1967","unstructured":"Johnson PC, Charalampous KD, Braun GA (1967) Absorption and excretion and tritiated haloperidol in man (a preliminary report). Int J Neuropsychiatry 3[suppl]1:524\u2013525","journal-title":"Int J Neuropsychiatry"},{"key":"BF02245121_CR26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0165-1781(83)90046-X","volume":"9","author":"D Kirch","year":"1983","unstructured":"Kirch D, Hattox S, Bell J, Murphy R, Freedman R (1983) Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal. Psychiatry Res 9:217\u2013223","journal-title":"Psychiatry Res"},{"key":"BF02245121_CR27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/clinchem\/29.4.624","volume":"29","author":"ER Korpi","year":"1983","unstructured":"Korpi ER, Phelps BH, Granger H, Chang W-H, Linnoila M, Meek VL, Wyatt RJ (1983) Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. Clin Chem 29:624\u2013628","journal-title":"Clin Chem"},{"key":"BF02245121_CR28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0165-1781(84)90074-X","volume":"11","author":"ER Korpi","year":"1984","unstructured":"Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ (1984) Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 11:259\u2013268","journal-title":"Psychiatry Res"},{"key":"BF02245121_CR29","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/0006-2952(85)90017-6","volume":"34","author":"ER Korpi","year":"1985","unstructured":"Korpi ER, Costakos DT, Wyatt RJ (1985) Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochem Pharmacol 34:2923\u20132927","journal-title":"Biochem Pharmacol"},{"key":"BF02245121_CR30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0022-3956(65)90012-9","volume":"3","author":"AA Kurland","year":"1965","unstructured":"Kurland AA, Huang CL, Hallam KJ, Hanlon TE (1965) Further studies of chlorpromazine metabolism and relapse rate. J Psychiatr Res 3:27\u201335","journal-title":"J Psychiatr Res"},{"key":"BF02245121_CR31","first-page":"483","volume-title":"Long-term effects of neuroleptics","author":"J Levine","year":"1980","unstructured":"Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, Steinbook R (1980) Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. In: Cattabeni F et al (eds) Long-term effects of neuroleptics. Raven Press, New York, pp 483\u2013493"},{"key":"BF02245121_CR32","first-page":"943","volume":"20","author":"PJ Lewi","year":"1970","unstructured":"Lewi PJ, Heykants JJP, Allewijn FTN, Dony JGH, Janssen PAJ (1970) Distribution and metabolism of neuroleptic drugs. Arzneimittelforschung (Drug Res) 20:943\u2013948","journal-title":"Arzneimittelforschung (Drug Res)"},{"key":"BF02245121_CR33","first-page":"355","volume":"26","author":"EG Lutz","year":"1965","unstructured":"Lutz EG (1965) Dissipation of phenothiazine effect and recurrence of schizophrenic psychosis. Dis Nerv Syst 26:355\u2013357","journal-title":"Dis Nerv Syst"},{"key":"BF02245121_CR34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00177561","volume":"96","author":"KK Midha","year":"1988","unstructured":"Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1988) Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology 96:206\u2013211","journal-title":"Psychopharmacology"},{"key":"BF02245121_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00429171","volume":"60","author":"P Muller","year":"1978","unstructured":"Muller P, Seeman P (1978) Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology 60:1\u201311","journal-title":"Psychopharmacology"},{"key":"BF02245121_CR36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00498552","volume":"299","author":"R Ohman","year":"1977","unstructured":"Ohman R, Larsson M, Nilsson IM, Engel J, Carlsson A (1977) Neurometabolic and behavioral effects of haloperidol in relation to drug level in serum and brain. Naunyn-Schmiedeberg's Arch Pharmacol 299:105\u2013114","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"BF02245121_CR37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0006-8993(87)91595-2","volume":"435","author":"EM Pich","year":"1987","unstructured":"Pich EM, Benfenati F, Farabegoli C, Fuxe K, Meller E, Aronsson M, Goldstein M, Agnati LF (1987) Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade. Brain Res 435:147\u2013152","journal-title":"Brain Res"},{"key":"BF02245121_CR38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archpsyc.1986.01800070059008","volume":"43","author":"D Pickar","year":"1986","unstructured":"Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenia patients. Arch Gen Psychiatry 43:669\u2013676","journal-title":"Arch Gen Psychiatry"},{"key":"BF02245121_CR39","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/cpt1972136931","volume":"13","author":"G Sakalis","year":"1972","unstructured":"Sakalis G, Curry SH, Mould GP, Lader MH (1972) Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther 13:931\u2013946","journal-title":"Clin Pharmacol Ther"},{"key":"BF02245121_CR40","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/0006-2952(77)90340-9","volume":"26","author":"P Seeman","year":"1977","unstructured":"Seeman P (1977) Anti-schizophrenic drugs \u2014 membrane receptor sites of action. Biochem Pharmacol 26:1741\u20131748","journal-title":"Biochem Pharmacol"},{"key":"BF02245121_CR41","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00004714-198712000-00023","volume":"7","author":"J Sramek","year":"1987","unstructured":"Sramek J, Herrera J, Costa J, Heh C (1987) Persistence of plasma neuroleptic levels after drug discontinuation. J Clin Psychopharmacol 7:436\u2013437","journal-title":"J Clin Psychopharmacol"},{"key":"BF02245121_CR42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0378-4347(00)84122-5","volume":"307","author":"AL Stoll","year":"1984","unstructured":"Stoll AL, Baldessarini RJ, Cohen BM, Finklestein SP (1984) Assay of plasma thioridazine and metabolites by high-performance liquid chromatography with amperometric detection. J Chromatogr Biomed Applic 307:457\u2013463","journal-title":"J Chromatogr Biomed Applic"},{"key":"BF02245121_CR43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0165-1781(87)90090-4","volume":"20","author":"T Sunderland","year":"1987","unstructured":"Sunderland T, Cohen BM (1987) Blood to brain distribution of neuroleptics. Psychiatry Res 20:299\u2013305","journal-title":"Psychiatry Res"},{"key":"BF02245121_CR44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1192\/bjp.119.553.589","volume":"119","author":"S Sved","year":"1971","unstructured":"Sved S, Perales A, Palaic D (1971) Chlorpromazine metabolism in chronic schizophrenics. Br J Psychiatry 119:589\u2013596","journal-title":"Br J Psychiatry"},{"key":"BF02245121_CR45","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF00179183","volume":"90","author":"CN Svendsen","year":"1986","unstructured":"Svendsen CN, Bird ED (1986) HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain. Psychopharmacology 90:316\u2013321","journal-title":"Psychopharmacology"},{"key":"BF02245121_CR46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-198702000-00005","volume":"7","author":"J Volavka","year":"1987","unstructured":"Volavka J, Cooper TB (1987) Review of haloperidol blood level and clinical response: looking through the window. J Clin Psychopharmacol 7:25\u201330","journal-title":"J Clin Psychopharmacol"},{"key":"BF02245121_CR47","first-page":"608","volume":"257","author":"S Xu","year":"1991","unstructured":"Xu S, Hatada Y, Black LE, Creese I, Sibley DR (1991) N-(p-Isothiocycanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. J Pharmacol Exp Ther 257:608\u2013615","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02245121_CR48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000138140","volume":"31","author":"G Zetler","year":"1985","unstructured":"Zetler G, Baumann GH (1985) Pharmacokinetics and effects of haloperidol in the isolated mouse. Pharmacology 31:318\u2013327","journal-title":"Pharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02245121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02245121\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02245121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T21:55:32Z","timestamp":1586555732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02245121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,8]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1992,8]]}},"alternative-id":["BF02245121"],"URL":"https:\/\/doi.org\/10.1007\/bf02245121","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,8]]}}}